RUTHERFORD, NEW JERSEY â€“ July 22, 2014Â â€“ Cancer Genetics, Inc. (NasdaqCM: CGIX), an emerging leader in DNA-based diagnostics, today announced that an overview of the Companyâ€™s business and commercial strategy will be given by CGIâ€™s Chief Executive Officer, Panna Sharma, at the Canaccord Genuity 34thÂ Annual Growth Conference, being held in Boston August 13-14, 2014.
Details of the Presentation are as follows:
Date:Â Â Â Â Â Â Â Â Â Â Â Â Â Â Thursday, August 14, 2014
Time:Â Â Â Â Â Â Â Â Â Â Â Â Â Â 1:30 PM Eastern Time
Location:Â Â Â Â Â Â Â Â InterContinental Hotel, Melbourne Room
About Cancer Genetics
Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, risks that we will not reach agreement on definitive acquisition agreements with Gentris, or that the Gentris and/or BioServe transactions will not close or, if either or both closes, will not realize the currently anticipated benefits, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company’s Form 10-K for the year ended December 31, 2013 and 10-Q for the quarter ended March 31, 2014 along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.